Skip to content
Learn More


iBio and CC-Pharming Initiate Joint Development of Coronavirus Vaccine

February 4, 2020

NEW YORK, Feb. 03, 2020 (GLOBE NEWSWIRE) — In response to investor and media inquiries regarding their initiatives to address the coronavirus outbreak, iBio, Inc. (NYSE AMERICAN:IBIO) and Beijing CC-Pharming Ltd., today announced their collaboration to develop and test a new 2019-nCoV vaccine to be manufactured using iBio’s FastPharming System™. The companies are expediting work as predictions about spread …

Read More

iBio Announces Collaboration with EdgePoint AI for Next Gen Quality in Biologics Manufacturing

December 24, 2019

NEW YORK, Dec. 23, 2019 (GLOBE NEWSWIRE) — iBio, Inc. (NYSE AMERICAN:IBIO) today announced that it has entered into a collaboration with EdgePoint AI, a division of Mateon Therapeutics, Inc. (OTCQB:MATN), to deploy EdgePoint’s proprietary artificial intelligence (“AI”)/blockchain-driven vision system for pharmaceutical manufacturing, known as TrustPoint Fabric. Initial implementation will occur at iBio’s state-of-the-art production …

Read More

iBio Reports Progress on its Bio-Better Rituximab Collaboration with CC-Pharming

December 16, 2019

Presentation Demonstrates Advantages of iBio’s Recently Launched FastGlycaneering Development Service™ – NEW YORK, Dec. 16, 2019 (GLOBE NEWSWIRE) — iBio, Inc. (NYSE AMERICAN:IBIO) presented results of the application of its new FastGlycaneering Development Service™ to enhance potency of recombinant proteins at last week’s Antibody Engineering & Therapeutics conference in San Diego, CA. Specifically, the presented data demonstrated  the ability to …

Read More

iBio Introduces FastGlycaneering Development Service™ to Power Recombinant Protein Production

December 10, 2019

NEW YORK, Dec. 10, 2019 (GLOBE NEWSWIRE) — iBio, Inc. (NYSE AMERICAN:IBIO) today unveiled the FastGlycaneering Development Service™, which includes an array of new glycosylation technologies for engineering high-performance recombinant proteins. Biopharmaceutical innovators and biosimilar producers will now be able to take advantage of low-cost afucosylation controls, oligomannose modification capabilities, and more custom glycosylation techniques using iBio’s …

Read More

iBio Joins Manufacturing USA’s Tissue Biofabrication Initiative

December 3, 2019

iBio to Support the 3D Bioprinting Industry with Enabling Biomaterials NEW YORK, Dec. 03, 2019 (GLOBE NEWSWIRE) — iBio, Inc. (NYSE AMERICAN:IBIO) today announced that it is now part of a new public-private Manufacturing USA initiative, the Advanced Regenerative Manufacturing Institute (“ARMI”). Headquartered in Manchester, New Hampshire, ARMI is the 12th Manufacturing USA Institute. ARMI brings …

Read More